Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Chang

Showing results (211-220 of 386) with videos related to

Pageof 39
Sort By:
Neuro-Oncology|March 14, 2020
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrenceRadhika Mathur, Yalan Zhang, Matthew R Grimmer, et al.
Frontiers in Neurology|February 14, 2022
T2 FLAIR Hyperintensity Volume Is Associated With Cognitive Function and Quality of Life in Clinically Stable Patients With Lower Grade GliomasTracy L Luks, Javier E Villanueva-Meyer, Christina Weyer-Jamora, et al.
International Journal of Radiation Oncology, Biology, Physics|July 6, 2004
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumorsSusan M Chang, Wendy Seiferheld, Walter Curran, et al.
Cancer Discovery|September 27, 2019
The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of VariationLin Wang, Husam Babikir, Sören Müller, et al.
Journal of Neuro-Oncology|June 14, 2021
A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendrogliomaNancy Ann Oberheim Bush, Jacob S Young, Yalan Zhang, et al.
Neuro-Oncology|December 23, 2023
Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expressionChristina L Appin, Chibo Hong, Abigail K Suwala, et al.
Investigational New Drugs|July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeSusan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Neuro-Oncology|May 21, 2026
Epidemiological and clinical data link depot medroxyprogesterone acetate to meningiomaBrooke C Braman, Martha A Cady, Allison A Merz-Herrala, et al.
Journal of Neuro-Oncology|August 26, 2009
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survivalSean M McBride, Daniel A Perez, Mei-Yin Polley, et al.
Neuro-Oncology|December 10, 2023
Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effortJoshua A Budhu, Ugonma N Chukwueke, Sadhana Jackson, et al.
Pageof 39

Showing results (211-220 of 386) with videos related to

Sort By:
Pageof 39
Neuro-Oncology|March 14, 2020
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrenceRadhika Mathur, Yalan Zhang, Matthew R Grimmer, et al.
Frontiers in Neurology|February 14, 2022
T2 FLAIR Hyperintensity Volume Is Associated With Cognitive Function and Quality of Life in Clinically Stable Patients With Lower Grade GliomasTracy L Luks, Javier E Villanueva-Meyer, Christina Weyer-Jamora, et al.
International Journal of Radiation Oncology, Biology, Physics|July 6, 2004
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumorsSusan M Chang, Wendy Seiferheld, Walter Curran, et al.
Cancer Discovery|September 27, 2019
The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of VariationLin Wang, Husam Babikir, Sören Müller, et al.
Journal of Neuro-Oncology|June 14, 2021
A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendrogliomaNancy Ann Oberheim Bush, Jacob S Young, Yalan Zhang, et al.
Neuro-Oncology|December 23, 2023
Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expressionChristina L Appin, Chibo Hong, Abigail K Suwala, et al.
Investigational New Drugs|July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeSusan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Neuro-Oncology|May 21, 2026
Epidemiological and clinical data link depot medroxyprogesterone acetate to meningiomaBrooke C Braman, Martha A Cady, Allison A Merz-Herrala, et al.
Journal of Neuro-Oncology|August 26, 2009
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survivalSean M McBride, Daniel A Perez, Mei-Yin Polley, et al.
Neuro-Oncology|December 10, 2023
Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effortJoshua A Budhu, Ugonma N Chukwueke, Sadhana Jackson, et al.
Pageof 39